10-Q: Lineage Cell Therapeutics Reports Q3 2026 Results

Lineage Cell Therapeutics, Inc. reported a substantial decrease in Q3 2026 revenues, alongside continued operating losses, though it highlighted progress in its cell therapy pipeline.

Summary

• Lineage Cell Therapeutics reported Q3 2026 revenues of $1.434 million, a significant decrease from $3.681 million in Q3 2025.
• For the nine months ended September 30, 2026, total revenues were $4.228 million, down from $7.948 million in the same period of 2025.
• The company incurred an operating loss of $7.314 million for the three months ended September 30, 2026, compared to a loss of $3.786 million in the prior year period.
• Net income attributable to Lineage was $4.232 million for Q3 2026, a significant swing from a net loss of $29.781 million in Q3 2025, largely due to changes in warrant liability valuation.
• Cash, cash equivalents, and marketable securities totaled $45.2 million as of September 30, 2026.
• The company acquired NeuroAirmid Therapeutics, Inc. on November 12, 2026, to advance its HUNT1 program for Huntington's Disease.
• Progress was noted in the OpRegen program with Roche and Genentech, showing sustained visual acuity gains and potential retinal restoration.
• The HUNT1 program is in Phase 1b/2a clinical study, and the OPC1 program is in Phase 1/2a clinical development.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to a significant decrease in revenues and continued operational losses, despite progress in preclinical and early-stage clinical programs.

Positives

• Sustained positive results for OpRegen in Phase 1/2a study, showing persistent gains in visual acuity and evidence of retinal restoration through 36 months.
• Acquisition of NeuroAirmid Therapeutics to strengthen the HUNT1 program for Huntington's Disease.
• Advancement of the COR1 program into preclinical animal testing with initial data expected in Q1 2027.
• Successful manufacturing of cGMP Grade material for the ReSonance (ANP1) program and progress in year two of the WDI collaboration.
• Demonstrated progress in the ILT1 program, achieving 3-liter scale for pluripotent cell production and differentiating into endodermal precursors.
• The company believes its current cash, cash equivalents, and marketable securities are sufficient to fund operations through at least twelve months from the issuance date of the financial statements.

Negatives

• Total revenues decreased by 61% to $1.434 million for the three months ended September 30, 2026, compared to $3.681 million in the prior year.
• Total revenues decreased by 47% to $4.228 million for the nine months ended September 30, 2026, compared to $7.948 million in the prior year.
• Operating expenses increased by 17% to $8.748 million for the three months ended September 30, 2026, compared to $7.467 million in the prior year.
• Research and development expenses increased by 35% to $12.826 million for the nine months ended September 30, 2026, compared to $9.491 million in the prior year.
• General and administrative expenses increased by 18% to $4.925 million for the three months ended September 30, 2026, compared to $4.191 million in the prior year.
• The company incurred a loss on impairment of an intangible asset of $14.8 million in Q2 2025 related to the VAC platform, with no comparable charge in the current period.
• The company expects to continue to incur significant operating losses for the foreseeable future and requires significant additional capital.

Risks

• The ongoing conflict and hostilities in the Middle East, including the 2026 Iran War, increase the risk of interruptions to operations in Jerusalem and clinical trial sites in Israel.
• The company's manufacturing operations are concentrated in Jerusalem, Israel, making it vulnerable to political and economic conditions, war, cyberattacks, or other conflicts.
• The company requires significant additional capital to fund its operations and expects to continue incurring losses for at least the next several years.
• Delays in clinical trials, regulatory approvals, or manufacturing processes could adversely affect the business.
• The company's ability to raise additional capital may be adversely impacted by unfavorable global economic conditions, volatility in financial markets, and geopolitical factors.
• The acquisition of NeuroAirmid Therapeutics includes significant contingent future payments based on clinical development and regulatory milestones.
• The company is subject to ongoing legal proceedings, including a motion for disclosure of documents related to an intercompany agreement, which could result in unfavorable rulings.

Future Outlook

The company expects to continue to incur significant operating losses for the foreseeable future and requires significant additional capital to fund its operations and continued development of its product candidates. The company believes its current cash, cash equivalents, and marketable securities are sufficient to fund planned operations through at least twelve months from the issuance date of the financial statements.

Management Comments

• Stock-based compensation expense for R&D was $269,000 for Q3 2026, up from $179,000 in Q3 2025.
• Stock-based compensation expense for G&A was $1,434,000 for Q3 2026, up from $1,020,000 in Q3 2025.
• Management believes that its cash, cash equivalents, and marketable securities will be sufficient to enable it to carry out its planned operations through at least twelve months from the issuance date of the accompanying condensed consolidated interim financial statements.

Industry Context

StockSavvy.ai notes that Lineage Cell Therapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, where significant investment in R&D is required with long development timelines and high failure rates. The company's focus on cell replacement therapies and its proprietary AlloSCOPE platform positions it within a growing but complex area of medicine.

Comparison to Industry Standards

• The OpRegen program's sustained efficacy through 36 months in slowing, stopping, or reversing disease progression in geographic atrophy (GA) is a positive indicator, though direct comparisons are difficult due to the early stage and specific nature of the therapy.
• The acquisition of NeuroAirmid Therapeutics for $2.4 million cash, 2.2 million shares, and significant contingent milestones aligns with industry practices for acquiring promising early-stage assets to bolster pipeline, though the contingent payments are substantial.
• The company's cash burn rate of approximately $20.9 million for the first nine months of 2026 is within the typical range for clinical-stage biotech companies, but highlights the ongoing need for substantial future funding.
• The decrease in collaboration revenues, particularly from the Roche agreement, reflects the typical project-based revenue recognition in biotech collaborations, which can fluctuate based on development stage and service requirements.

Legal Proceedings

• A motion for disclosure of documents was received by CCN in April 2023 related to an intercompany Collaboration and License Agreement between Lineage and CCN, alleging an unfairly priced interested party transaction. The third-party valuation firm's report in June 2025 stated consideration paid by Lineage to CCN was insufficient. The Court granted HBL's motion on March 12, 2026, allowing HBL to potentially initiate separate proceedings.

Related Party Transactions

• In January 2025, the company sold common shares and warrants to Broadwood Partners, L.P., an affiliate of Neal Bradsher, a member of the board of directors.

Stakeholder Impact

• Shareholders may experience dilution if additional equity is issued to raise capital.
• The company's continued need for significant funding and ongoing operating losses may impact investor confidence.
• Progress in clinical programs like OpRegen and HUNT1 could lead to future value creation for shareholders.
• The acquisition of NeuroAirmid Therapeutics involves substantial contingent payments, which could impact future financial performance and shareholder value if milestones are met.

Next Steps

• Continue Phase 2a development of OpRegen with Roche and Genentech.
• Advance the HUNT1 program for Huntington's Disease following the acquisition of NeuroAirmid Therapeutics.
• Conduct preclinical animal testing for COR1, with initial data expected in Q1 2027.
• Continue development of ReSonance (ANP1) with WDI, including discussions with the Danish Medicines Agency.
• Continue development of ILT1 for Type 1 Diabetes, focusing on large-scale production of pluripotent cells.
• Evaluate RND1 and PNC1 programs.
• Continue long-term follow-up of patients in the OpRegen Phase 1/2a study.

Key Dates

Recommendation

The company shows promising clinical progress in key programs like OpRegen, with sustained positive data. However, the significant decrease in revenue, rising operating costs, and substantial ongoing need for capital to fund future development present considerable financial risks. The acquisition of NeuroAirmid adds another layer of contingent financial obligation. Therefore, a 'hold' recommendation is appropriate, pending clearer signs of revenue stabilization and a more defined path to profitability or successful, non-dilutive capital raises.

Keywords

cell therapy, biotechnology, clinical-stage, drug development, regenerative medicine, OpRegen, Huntington's Disease, Age-Related Macular Degeneration